Jefferies maintains Endo buy rating

Endo Pharmaceuticals Holdings, Inc. was reiterated at a buy rating with a $33 price target by Jefferies & Co. Inc. analyst David Windley after third-quarter results showed lower-than-expected operating expenses, which drove a $0.04 earnings per share upside versus Jefferies estimates of $0.54. Revenues of $245.2 million were $2 million lower than Jefferies forecast, but Jefferies believes management's guidance range is achievable. Shares of the Chadds Ford, Pa.-based pharmaceutical company were down $1.63, or 6.18%, at $24.75 on volume of 3,024,838 shares versus the three-month running average of 1,062,470 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.